Rapport Therapeutics, Inc. (RAPP)
(Delayed Data from NSDQ)
$28.93 USD
+2.05 (7.63%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $28.90 -0.03 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RAPP 28.93 +2.05(7.63%)
Will RAPP be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RAPP based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for RAPP
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
RAPP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RAPP
Is RAPP ready to move higher? 20 Day Moving Average Support shows up after rallying 7.63%
Is RAPP preparing to trend higher? 20 Day Moving Average Support shows up after sinking 1.86%
Is RAPP set to breakout? Bollinger Band Squeeze shows up after plummeting 5.42%
Is RAPP signaling a buying opportunity? Crossed Above 20 Day Moving Average shows up after rallying 9.37%
RAPP forms 20 Day Moving Average Resistance on October 27